WithdrawnNCT00672464
Cardio Risk of Acute Schizophrenia Olanzapine Duke
Medication studyAges 18–60United States
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- Butner and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateApril 2008
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00672464
- Official title
Show the full official title
Combined Treatment of Cardiovascular Risk Factors In Newly Admitted Patients With Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine And Matched Controls
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Butner · Durham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Does this study involve medication?
Yes. The study involves medication, including Olanzapine, Metformin and Simvastatin.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
Want to explore more studies?
Explore studiesRelated studies
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolarity type I